Add disclaimer about CYP2D6

[LunaUrsa]

"I realized that when you talk about DXM, there is no information about enzymatic variations between users and their impact on the effects of DXM.

Indeend, 10% of population is CYP2D6-deprived and it changes the effects of DXM, as it is then less metabolized in DXO.
Effects are probably less dissociatives and more serotoninergic/stimulants.
So the plateau scale is not adapted to slow metabolizers. The effects described do not really correspond to their own.
This can put them at risk, as to achieve satisfactory levels of dissociation, they may need to take doses that produce disproportionate serotonergic and noradrenergic effects, with the associated risks.

(i've written an article about it, but in french, sorry. DeepL could help translate it if you're interested in reading it : https://www.psychonaut.fr/Thread-%C3%89tudes-DXM-et-m%C3%A9tabolisation-CYP2D6-l-%C3%A9chelle-des-paliers-est-elle-si-pertinente)

Anyway my conclusion is : we need to stop presenting this scale as absolute knowledge and put it back into context: a subjective scale, proposed by a small group of psychonaut pioneers, probably (statistically) belonging to the majority phenotypic group.

I really think your tool should include at least a warning about it.

Thanks for reading !" - Lorre on discord